GE HealthCare Technologies PDx — Total revenues decreased by 2.5% to $770.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.8%, from $632.00M to $770.00M. Over 4 years (FY 2021 to FY 2025), PDx — Total revenues shows an upward trend with a 9.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market adoption or higher pricing power for diagnostic agents, while a decrease suggests competitive pressure or reduced procedure volumes.
Represents the total gross income generated by the Pharmaceutical Diagnostics segment through the sale of contrast media...
Comparable to revenue metrics for life sciences or diagnostic imaging divisions at diversified healthcare conglomerates.
gehc_segment_pdx_total_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $504.50M | $504.50M | $504.50M | $484.00M | $478.00M | $522.00M | $474.00M | $558.00M | $568.00M | $589.00M | $591.00M | $599.00M | $639.00M | $625.00M | $645.00M | $632.00M | $729.00M | $749.00M | $790.00M | $770.00M |
| QoQ Change | — | +0.0% | +0.0% | -4.1% | -1.2% | +9.2% | -9.2% | +17.7% | +1.8% | +3.7% | +0.3% | +1.4% | +6.7% | -2.2% | +3.2% | -2.0% | +15.3% | +2.7% | +5.5% | -2.5% |
| YoY Change | — | — | — | — | -5.3% | +3.5% | -6.0% | +15.3% | +18.8% | +12.8% | +24.7% | +7.3% | +12.5% | +6.1% | +9.1% | +5.5% | +14.1% | +19.8% | +22.5% | +21.8% |